# Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients

> **NCT02702739** · PHASE4 · COMPLETED · sponsor: **Azienda Ospedaliera San Camillo Forlanini** · enrollment: 270 (actual)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **DRUG:** Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks

## Key facts

- **NCT ID:** NCT02702739
- **Lead sponsor:** Azienda Ospedaliera San Camillo Forlanini
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-12
- **Final completion:** 2016-02
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2016-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02702739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02702739, "Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT02702739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*